Literature DB >> 18776941

Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice.

Maciej Kujawski1, Marcin Kortylewski, Heehyoung Lee, Andreas Herrmann, Heidi Kay, Hua Yu.   

Abstract

The underlying molecular mechanisms that cause immune cells, mediators of our defense system, to promote tumor invasion and angiogenesis remain incompletely understood. Constitutively activated Stat3 in tumor cells has been shown to promote tumor invasion and angiogenesis. Therefore, we sought to determine whether Stat3 activation in tumor-associated inflammatory cells has a similar function. We found that Stat3 signaling mediates multidirectional crosstalk among tumor cells, myeloid cells in the tumor stroma, and ECs that contributes to tumor angiogenesis in mice. Myeloid-derived suppressor cells and macrophages isolated from mouse tumors displayed activated Stat3 and induced angiogenesis in an in vitro tube formation assay via Stat3 induction of angiogenic factors, including VEGF and bFGF. Stat3-regulated factors produced by both tumor cells and tumor-derived myeloid cells also induced constitutive activation of Stat3 in tumor endothelium, and inhibiting Stat3 in ECs substantially reduced in vitro tumor factor-induced endothelial migration and tube formation. In vivo assays demonstrated the requirement for Stat3 signaling in tumor-associated myeloid cells for tumor angiogenesis. Our results indicate that, by virtue of the ability of Stat3 in tumor cells and tumor-derived myeloid cells to upregulate expression of factors that activate Stat3 in ECs, Stat3 mediates multidirectional crosstalk among tumor cells, tumor-associated myeloid cells, and ECs that contributes to tumor angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18776941      PMCID: PMC2528912          DOI: 10.1172/JCI35213

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  48 in total

1.  VEGF differentially activates STAT3 in microvascular endothelial cells.

Authors:  Manuela Bartoli; Dan Platt; Tahira Lemtalsi; Xiaolin Gu; Steven E Brooks; Mario B Marrero; Ruth B Caldwell
Journal:  FASEB J       Date:  2003-06-17       Impact factor: 5.191

Review 2.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

3.  Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo.

Authors:  G Niu; R Heller; R Catlett-Falcone; D Coppola; M Jaroszeski; W Dalton; R Jove; H Yu
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

4.  IL-1 is required for tumor invasiveness and angiogenesis.

Authors:  Elena Voronov; Dror S Shouval; Yakov Krelin; Emanuela Cagnano; Daniel Benharroch; Yoichiro Iwakura; Charles A Dinarello; Ron N Apte
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-21       Impact factor: 11.205

Review 5.  Does the immune system see tumors as foreign or self?

Authors:  Drew Pardoll
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

6.  Tissue-specific microvascular endothelial cell lines from H-2K(b)-tsA58 mice for studies of angiogenesis and metastasis.

Authors:  Robert R Langley; Karen M Ramirez; Rachel Z Tsan; Melissa Van Arsdall; Monique B Nilsson; Isaiah J Fidler
Journal:  Cancer Res       Date:  2003-06-01       Impact factor: 12.701

Review 7.  The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages.

Authors:  Paola Allavena; Antonio Sica; Graziella Solinas; Chiara Porta; Alberto Mantovani
Journal:  Crit Rev Oncol Hematol       Date:  2007-10-29       Impact factor: 6.312

8.  Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity.

Authors:  Cecilia Melani; Claudia Chiodoni; Guido Forni; Mario P Colombo
Journal:  Blood       Date:  2003-05-15       Impact factor: 22.113

9.  Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis.

Authors:  Daoyan Wei; Xiangdong Le; Leizhen Zheng; Liwei Wang; Jennifer A Frey; Allen C Gao; Zhihai Peng; Suyun Huang; Henry Q Xiong; James L Abbruzzese; Keping Xie
Journal:  Oncogene       Date:  2003-01-23       Impact factor: 9.867

10.  STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation.

Authors:  Chien-kuo Lee; Regina Raz; Ramon Gimeno; Rachel Gertner; Birte Wistinghausen; Kenichi Takeshita; Ronald A DePinho; David E Levy
Journal:  Immunity       Date:  2002-07       Impact factor: 31.745

View more
  244 in total

1.  Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1.

Authors:  Rongze Lu; Maciej Kujawski; Hao Pan; John E Shively
Journal:  Cancer Res       Date:  2012-03-09       Impact factor: 12.701

Review 2.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

3.  Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells.

Authors:  Yuelong Liu; Xiaoyu Xiang; Xiaoying Zhuang; Shuangyin Zhang; Cunren Liu; Ziqiang Cheng; Sue Michalek; William Grizzle; Huang-Ge Zhang
Journal:  Am J Pathol       Date:  2010-03-26       Impact factor: 4.307

Review 4.  Dual roles for immunity in gastrointestinal cancers.

Authors:  Cristina Ferrone; Glenn Dranoff
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

Review 5.  Interleukin-6 in bone metastasis and cancer progression.

Authors:  Tasnim Ara; Yves A Declerck
Journal:  Eur J Cancer       Date:  2010-03-23       Impact factor: 9.162

Review 6.  Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.

Authors:  Tim F Greten; Xin W Wang; Firouzeh Korangy
Journal:  Gut       Date:  2015-02-09       Impact factor: 23.059

Review 7.  Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer.

Authors:  Sabrin Husein Albeituni; Chuanlin Ding; Jun Yan
Journal:  Cancer J       Date:  2013 Nov-Dec       Impact factor: 3.360

8.  Immunosuppressive CD14+HLA-DRlo/neg monocytes are elevated in pancreatic cancer and "primed" by tumor-derived exosomes.

Authors:  Naureen Javeed; Michael P Gustafson; Shamit K Dutta; Yi Lin; William R Bamlet; Ann L Oberg; Gloria M Petersen; Suresh T Chari; Allan B Dietz; Debabrata Mukhopadhyay
Journal:  Oncoimmunology       Date:  2016-11-02       Impact factor: 8.110

9.  Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis.

Authors:  Jeremy D Waight; Colleen Netherby; Mary L Hensen; Austin Miller; Qiang Hu; Song Liu; Paul N Bogner; Matthew R Farren; Kelvin P Lee; Kebin Liu; Scott I Abrams
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

Review 10.  Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer.

Authors:  Sergei I Grivennikov; Michael Karin
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-16       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.